Scrip
Biosimilar EPO and novel antidiabetics lead raft of Japanese approvals
21 January 2010
Ian Haydock
Please Login to read the full article.
21 January 2010
Ian Haydock
A large batch of new products has received final approval from Japan's ministry of health, labour and welfare, including a biosimilar erythropoietin, Novartis's DPP-4 inhibitor Equa (vildagliptin), and Novo Nordisk's GLP-1 analogue Victoza (liraglutide).
These and the other products given...
Please Login to read the full article.
RELATED CONTENT
FEATURES
- Face to Face with Sandoz's "growth guy" Jeff George
- Interview: European Medicines Agency gets serious about its global strategy
SCIENCE
- Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial
- Fasting glucose and postprandial glycemia: which is the best target for improving outcomes? The Apollo and 4-T Trials
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
